Haemonetics (HAE) Net Income towards Common Stockholders (2009 - 2026)

Haemonetics' Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 134.75% year-over-year to -$20.1 million; the TTM figure through Mar 2026 stood at $97.3 million (down 41.95% YoY), while the FY2026 annual figure was $97.3 million, down 41.97% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$20.1 million, down from $44.7 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $58.0 million in Q1 2025, with the low at -$20.1 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is $33.1 million (2022), against an average of $29.5 million.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders soared 546.27% in 2022, then plunged 134.75% in 2026.
• Haemonetics' Net Income towards Common Stockholders stood at $32.9 million in 2022, then fell by 5.17% to $31.2 million in 2023, then rose by 20.09% to $37.5 million in 2024, then rose by 19.25% to $44.7 million in 2025, then sank by 145.03% to -$20.1 million in 2026.
• Business Quant data shows HAE's Net Income towards Common Stockholders at -$20.1 million in Q1 2026, $44.7 million in Q4 2025, and $38.7 million in Q3 2025.